Skip to main content
Premium Trial:

Request an Annual Quote

Invitrogen Adds to RNAi Product line with Sequitur Acquisition

NEW YORK, Nov. 4 (GenomeWeb News) - Invitrogen said today that it has acquired privately held RNAi technology firm Sequitur of Natick, Mass.

Financial terms of the acquisition were not disclosed.

Claude Benchimol, Invitrogen's senior vice president of R&D, said that the acquisition will add to Invitrogen's "growing RNAi platform." Benchimol said that Sequitur's Stealth RNAi technology, which uses proprietary chemically modified synthetic RNAi molecules, performs "better than conventional short-interfering RNA" and can be combined with Invitrogen's Lipofectamine transfection reagents.

Invitrogen's RNAi product line, marketed under the Block-it trade name, includes transfection agents, vectors, oligonucleotides, and other products.

"With its patent position, we believe Sequitur Inc.'s Stealth technology will prevail as the standard method for how researchers perform RNAi," said Invitrogen CEO Gregory Lucier.

The Scan

Highly Similar

Researchers have uncovered bat viruses that are highly similar to SARS-CoV-2, according to Nature News.

Gain of Oversight

According to the Wall Street Journal, the Biden Administration is considering greater oversight of gain-of-function research.

Lasker for mRNA Vaccine Work

The Scientist reports that researchers whose work enabled the development of mRNA-based vaccines are among this year's Lasker Award winners

PLOS Papers on Causal Variant Mapping, Ancient Salmonella, ALK Fusion Test for NSCLC

In PLOS this week: MsCAVIAR approach to map causal variants, analysis of ancient Salmonella, and more.